5-Amino-1MQ 50mg (60 Capsules)
5-amino-1MQ is a small molecule that blocks the activity of the enzyme called nicotinamide N-methyltransferase (NNMT). NNMT is a very important component in metabolism and energy and is predominantly active in fat tissue. By blocking NNMT, 5-amino-1MQ stimulates an increase in nicotinamide adenine dinucleotide (NAD+), a cofactor that is central to cellular metabolism, thereby increasing metabolic rate and activating a gene called sirtuin-1 (SIRT1).
SIRT1 is also known as the "longevity gene" because of its role in reducing the risk of diabetes, obesity, metabolic syndrome, atherosclerosis and other forms of cardiovascular disease, kidney disease, liver disease, neurodegeneration, and cancer. Research in mice given 5-amino-1MQ showed a 7% reduction in body mass over 10 days without any changes in food intake, compared to controls. Research has shown that decreasing NNMT may help shrink fat cells and reduce the size of fat deposits. Acetyl Hexapeptide-3 (Argireline) 200mg (Topical)
Adipotide (FTPP) 10mg
AHK (Tripeptide-3) 200mg (Topical)
AHK-Cu 200mg (Topical)
AICAR 50mg
AICAR is an analogue of adenosine monophosphate. It has been used clinically to protect against cardiac ischemia following heart attack. AICAR has antioxidant properties and may therefore help to slow the physiologic signs of aging. There is ongoing research into the use of AICAR to mediate the effects of diabetes, auto-immune diseases, and other inflammatory conditions.
AOD9604 6mg
AOD9604 is a modified version of the hGH fragment 176-191 peptide (contains a di-sulfide bridge) and thus a derivative of human growth hormone (hGH). Originally developed as a lipolytic (fat burning) compound, AOD9604 has shown benefit in studies of heart disease, osteoarthritis/cartilage repair, and metabolic syndrome. AOD9604 stimulates lipolysis (the breakdown or destruction of fat) and inhibits lipogenesis in animal studies.
ARA-290 16mg
B7-33 6mg
B7-33 exibits potent anti-fibrotic effects. It is under active research and investigation as a means of reducing fibrosis in acute and chronic diseases like heart failure, lung inflammation, kidney and more. In animal studies, B7-33 has reduced fibrosis by roughly 50%, leading to prolonged survival following injury and offering the first new means of treating heart failure in 20 years. It has been shown to reduce excessive scar formation following cardiac injury. It has also shown promise in the treatment of certain vascular disorders as well as preeclampsia of pregnancy.
Botulinum toxin
BPC 157 500mcg (60 Capsules)
BPC-157 has undergone a great deal of research because its healing abilities extend well beyond the lining of the stomach. Studies in animal models indicate that BPC-157 can enhance angiogenesis, promote wound healing, stimulate collagen synthesis, modulate the inflammatory response, and protect against oxidative stress. The peptide has shown benefits in animal models with inflammatory bowel disease, GI ulcers, musculoskeletal injuries, heart damage, eye injuries and neurological damage. Research has shown that the oral bioavailability of BPC-157 is quite high.